Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-DPYD Recombinant Antibody (10C16) (V2LY-0425-LY891)


See all DPYD antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat, Dog, Cattle, Pig
Clone
10C16
Antibody Isotype
IgG2a, κ
Application
WB, IP, IF, ELISA

Basic Information

Immunogen
Amino acids 957-989 near the C-terminus of human DPYD.
Host Species
Mouse
Specificity
Human, Mouse, Rat, Dog, Cattle, Pig
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal Antibody
Application Notes
ApplicationNote
ELISA1:100-1:1,000
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
Gelatin & PBS
Preservative
Sodium Azide
Concentration
0.2 mg/ml
Purity
>95% as determined by analysis by SDS-PAGE
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Dihydropyrimidine Dehydrogenase
Entrez Gene ID
Human1806
Mouse99586
Rat81656
Dog479935
UniProt ID
HumanQ12882
MouseQ8CHR6
RatO89000
DogE2RSQ9
Function
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
Biological Process
Beta-alanine biosynthetic process Source: UniProtKB-UniPathway
Purine nucleobase catabolic process Source: UniProtKB
Pyrimidine nucleobase catabolic process Source: UniProtKB
Thymidine catabolic process Source: UniProtKB
Thymine catabolic process Source: UniProtKB
Uracil catabolic process Source: UniProtKB
Cellular Location
Cytoplasm
Involvement in disease
Dihydropyrimidine dehydrogenase deficiency (DPYDD):
A metabolic disorder with large phenotypic variability, ranging from no symptoms to a convulsive disorder with motor and mental retardation. It is characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil.
More Infomation

Hamzic, S., Schärer, D., Offer, S. M., Meulendijks, D., Nakas, C., Diasio, R. B., ... & Largiadèr, C. R. (2021). Haplotype structure defines effects of common DPYD variants c. 85T> C (rs1801265) and c. 496A> G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity. British journal of clinical pharmacology, 87(8), 3234-3243.

Wigle, T. J., Povitz, B. L., Medwid, S., Teft, W. A., Legan, R. M., Lenehan, J., ... & Kim, R. B. (2021). Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clinical and translational science, 14(4), 1338-1348.

Naushad, S. M., Hussain, T., Alrokayan, S. A., & Kutala, V. K. (2021). Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. The Journal of Gene Medicine, 23(1), e3289.

Wörmann, B., Bokemeyer, C., Burmeister, T., Köhne, C. H., Schwab, M., Arnold, D., ... & Hofheinz, R. D. (2020). Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncology research and treatment, 43(11), 628-636.

Coenen, M. J., Paulussen, A. D., Breuer, M., Lindhout, M., Tserpelis, D. C., Steyls, A., ... & van den Bosch, B. J. (2019). Evolution of dihydropyrimidine dehydrogenase diagnostic testing in a single center during an 8-year period of time. Current Therapeutic Research, 90, 1-7.

Murphy, C., Byrne, S., Ahmed, G., Kenny, A., Gallagher, J., Harvey, H., ... & Bird, B. (2018). Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experience. Dose-Response, 16(4), 1559325818803042.

Shrestha, S., Zhang, C., Jerde, C. R., Nie, Q., Li, H., Offer, S. M., & Diasio, R. B. (2018). Gene‐specific variant classifier (DPYD‐varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clinical Pharmacology & Therapeutics, 104(4), 709-718.

Henricks, L. M., Siemerink, E. J., Rosing, H., Meijer, J., Goorden, S. M., Polstra, A. M., ... & van Kuilenburg, A. B. (2018). Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. International Journal of Cancer, 142(2), 424-430.

Gokare, P., Finnberg, N. K., Abbosh, P. H., Dai, J., Murphy, M. E., & El-Deiry, W. S. (2017). P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Scientific reports, 7(1), 1-12.

Del Re, M., Restante, G., Di Paolo, A., Crucitta, S., Rofi, E., & Danesi, R. (2017). Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. Current Pharmaceutical Design, 23(14), 2028-2034.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-DPYD Recombinant Antibody (10C16)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quote Online Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry